CVS Health Drives Drug Affordability by Promoting Competition

23.09.25 14:23 Uhr

Werte in diesem Artikel
Aktien

65,51 EUR 0,77 EUR 1,19%

Indizes

PKT PKT

17.965,2 PKT -33,6 PKT -0,19%

3.318,2 PKT -0,7 PKT -0,02%

6.654,2 PKT -2,7 PKT -0,04%

CVS Health CVS is off to a strong start in the 2026 Pharmacy Benefit Manager (“PBM”) selling season, with Caremark dominating in this highly competitive marketplace. The unit is tracking in line with its historical upper 90% retention rate. Caremark has a long history of driving down prescription and pharmacy costs by increasing competition.Recently, it partnered with Novo Nordisk to significantly increase access to Wegovy, a GLP-1 drug, for its members at a more affordable price. On July 1, CVS Health took a formulary action to prefer Wegovy, removing Eli Lilly’s weight management drug Zepbound from the Standard Control, Advanced Control and Value formularies. Furthermore, CVS also pairs the medication with its weight management program, where participants have achieved double-digit % weight loss at 12 months, regardless of the drug they use.Weight management drugs like the GLP-1 can significantly improve health outcomes, but their exorbitant prices often limit access for many. CVS expects its decision could save an estimated 10-15% year over year in the anti-obesity medication space for members using its template formularies.Last year, Caremark removed Humira from all its major national commercial template formularies, driving the use of Humira biosimilars instead. These alternatives, which have no clinically meaningful difference from their reference product, represent one of the biggest opportunities for reducing drug costs for employers and consumers. The move has already generated more than $1 billion in savings for CVS clients.Effective Jan. 1, 2026, CVS will begin providing outpatient prescription drug benefits for approximately 587,000 CalPERS members enrolled in Basic or Medicare HMO and PPO plans. The five-year contract emphasizes CVS’ ability to deliver affordable drug benefits and its commitment to performance guarantees in key areas such as managing pharmacy cost trends and ensuring clinical quality.Latest Developments From CVS CompetitorsUnitedHealth Group’s UNH Optum Rx has raised reimbursement minimums for branded drugs for approximately 2,300 independent pharmacies nationwide, those not affiliated with a pharmacy services administrative organization, chain or other entity. This move, which went into effect on Sept. 1, 2025, will support the long-term sustainability of pharmacies, which play a critical role in patient care. Amazon AMZN recently announced the expansion of its third-party logistics product, Amazon Multi-Channel Fulfillment (“MCF”), to support merchants on SHEIN, Shopify and Walmart. By leveraging one shared inventory pool with Fulfillment by Amazon, Amazon MCF empowers businesses to simplify their fulfillment, increase sales through existing channels and quickly launch in new online stores.CVS Stock Performance, Valuation and EstimatesYear to date, CVS Health shares have surged 67.4% against the industry’s 1% fall. Image Source: Zacks Investment ResearchCVS Health is trading at a forward five-year price/earnings (P/E) of 10.87X, lower than the industry average of 15.05X. The stock has a Value Score of A.Image Source: Zacks Investment ResearchHere’s how analyst estimates for the company’s 2025 and 2026 presently stand. Image Source: Zacks Investment ResearchCVS currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Zacks Names #1 Semiconductor StockThis under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: CVS Health und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf CVS Health

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf CVS Health

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu CVS Health Corp

Wer­bung

Analysen zu CVS Health Corp

DatumRatingAnalyst
05.06.2019CVS Health BuyStandpoint Research
15.04.2019CVS Health PerformOppenheimer & Co. Inc.
12.04.2019CVS Health Market PerformBMO Capital Markets
18.12.2018CVS Health OverweightBarclays Capital
26.10.2018CVS Health Peer PerformWolfe Research
DatumRatingAnalyst
05.06.2019CVS Health BuyStandpoint Research
12.04.2019CVS Health Market PerformBMO Capital Markets
18.12.2018CVS Health OverweightBarclays Capital
30.01.2018CVS Health Strong BuyNeedham & Company, LLC
02.01.2018CVS Health BuyNeedham & Company, LLC
DatumRatingAnalyst
15.04.2019CVS Health PerformOppenheimer & Co. Inc.
26.10.2018CVS Health Peer PerformWolfe Research
28.06.2017CVS Health HoldNeedham & Company, LLC
02.02.2017CVS Health NeutralRobert W. Baird & Co. Incorporated
22.06.2016CVS Health HoldDeutsche Bank AG
DatumRatingAnalyst
25.07.2005Update Longs Drug Stores Corp.: UnderperformBear Stearns

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für CVS Health Corp nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen